Posted by Michael Wonder on 07 Oct 2020
Samsung Bioepis and Biogen announce EMA filing acceptance of SB11, a proposed biosimilar referencing Lucentis (ranibizumab)
6 October 2020 - Samsung Bioepis and Biogen today announced that the EMA has accepted for review the marketing authorisation Application for SB11, a proposed biosimilar referencing Lucentis (ranibizumab).
If approved, SB11 will join a growing number of biosimilars developed by Samsung Bioepis and commercialised by Biogen.
